X0609 4 2026-08-06 0001839970 BlossomHill Therapeutics, Inc. BLSM 0001772233 Li Yishan false C/O BLOSSOMHILL THERAPEUTICS, INC. 10255 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 true true true false Executive Chairman 0 Common Stock 2026-08-10 4 C 0 1600682 A 1600682 I By The Li and Cui Family Trust Common Stock 2026-08-10 4 C 0 113435 A 1714117 I By The Li and Cui Family Trust Common Stock 2026-08-10 4 C 0 124779 A 124779 I By RongShan, LLC Common Stock 1067121 D Common Stock 1067121 I By Spouse Employee Stock Option (Right to Buy) 16 2026-08-06 4 A 0 112701 0 A 2036-08-05 Common Stock 112701 112701 D Series Angel Preferred Stock 2026-08-10 4 C 0 1600682 D Common Stock 1600682 0 I By The Li and Cui Family Trust Series B Preferred Stock 2026-08-10 4 C 0 113435 D Common Stock 113435 0 I By The Li and Cui Family Trust Series B Preferred Stock 2026-08-10 4 C 0 124779 D Common Stock 124779 0 I By RongShan, LLC Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. /s/ Vincent Liptak, Attorney-in-Fact 2026-08-10